On-the-ground application of the

Auffret, Marine; Rolland, Benjamin; Caous, Anne-Sylvie; Gaboriau, Louise; Deheul, Sylvie; Bordet, Regis; Gautier, Sophie

Document type :

Article dans une revue scientifique: Article original

DOI :

10.1111/fcp.12332

PMID :

29143356

Permalink :

http://hdl.handle.net/20.500.12210/16090

Title :

On-the-ground application of the

Author(s) :

Auffret, Marine [Auteur]
Rolland, Benjamin [Auteur]
Caous, Anne-Sylvie [Auteur]
Gaboriau, Louise [Auteur]
Deheul, Sylvie [Auteur]
Bordet, Regis [Auteur]

Troubles cognitifs dégénératifs et vasculaires - U1171
Troubles cognitifs dégénératifs et vasculaires - U 1171 [TCDV]
Troubles cognitifs dégénératifs et vasculaires - U 1171 [TCDV]
Gautier, Sophie [Auteur]
Troubles cognitifs dégénératifs et vasculaires - U1171
Troubles cognitifs dégénératifs et vasculaires - U 1171 [TCDV]
Troubles cognitifs dégénératifs et vasculaires - U 1171 [TCDV]

Journal title :

Fundamental & clinical pharmacology

Abbreviated title :

Fundam Clin Pharmacol

Publication date :

2017-11-15

ISSN :

1472-8206

English keyword(s) :

off-label
community pharmacist
baclofen
drug dispensing
France
alcohol dependence

HAL domain(s) :

Sciences du Vivant [q-bio]

English abstract : [en]

The 'temporary recommendation for use' (TRU) is a French novel regulatory measure for off-label drug. The first TRU to be issued by the French drug agency (in March 2014) pertained to the off-label use of baclofen for ...
Show more >The 'temporary recommendation for use' (TRU) is a French novel regulatory measure for off-label drug. The first TRU to be issued by the French drug agency (in March 2014) pertained to the off-label use of baclofen for alcohol dependence (AD). We performed a questionnaire-based survey of the on-the-ground application of the baclofen TRU among community pharmacies in northern France. A pharmacist from 70 of the 219 pharmacies contacted (response rate: 32.0%) completed the questionnaire. The mean ± standard deviation number of off-label baclofen prescriptions for AD was 2.3 ± 2.2 per pharmacy per month. 65.2% of these prescriptions were issued by primary care physicians. 65.7% of the pharmacists had never seen 'TRU' written on the prescription, and 80.3% delivered a prescription without checking whether the patient had been included by the prescriber in the TRU. The main criterion used to identify off-label prescribing was the patient's medical history (according to 74.6% of pharmacists) and the prescription of an above-threshold dose (73.1%). 87.1% of the pharmacists were aware of the baclofen TRU, and 42.9% had actually read the document. 17.9% of the pharmacists estimated that the TRU had changed their attitude to off-label baclofen prescription, and 29.9% (20 out of 67) of them wanted to be more involved in the TRU process. Community pharmacists were well informed about the off-label use of baclofen for AD and the TRU. However, a majority of baclofen prescribers did not fulfill the TRU requirements while a majority of pharmacists did not exert any control over these off-label prescriptions. In practice, in 2015 the TRU measure had thus a limited impact on both the baclofen prescribing and delivery practices.Show less >

Language :

Anglais

Audience :

Internationale

Popular science :

Non

Administrative institution(s) :

CHU Lille
CNRS
Inserm
Université de Lille

Collections :

Lille Neurosciences & Cognition (LilNCog) - U 1172

Research team(s) :

Troubles cognitifs dégénératifs et vasculaires

Submission date :

2019-11-27T13:05:24Z

On-the-ground application of the BibTeX CSV Excel RIS

On-the-ground application of the

BibTeX

CSV

Excel

RIS